Pfizer buys Global Blood Therapeutics for $5.4 bilion
Pfizer is boosting its pipeline with a $5.4 billion deal for blood disorder drugmaker Global Blood Therapeutics, the latest in a series of acquisitions to combat a potential slowdown in Covid-19 products demand as cases fall.
Business
• 08 Aug 22
